Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil
Authors:
- Dorota ZolkowskaDZDorota Zolkowska
- Raka JainRJRaka Jain
- Richard B. RothmanRRRichard B. Rothman
- John S. PartillaJPJohn S. Partilla
- Bryan L. RothBRBryan L. Roth
- Vincent SetolaVSVincent Setola
- Thomas E. PrisinzanoThomas E. Prisinzano
- Michael H. BaumannMBMichael H. Baumann
- 1 May 2009
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 329 (2) , 738-746
Abstract
Modafinil is prescribed for numerous medical conditions, but the drug9s mechanism of action is unclear. Here, we examined the interaction of modafinil with receptors and transporters in vitro and compared pharmacological effects of the drug with those produced by indirect dopamine (DA) agonists 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) and (+)-methamphetamine (METH). Modafinil was screened at various receptors and transporters using binding assays. Transporter-mediated uptake and release were examined in rat brain synaptosomes. Effects of modafinil on motor activity and neurochemistry were determined in rats undergoing in vivo microdialysis in nucleus accumbens. Of the receptors and transporters assayed, modafinil displayed measurable potency only at DA transporters (DAT), inhibiting [3H]DA uptake, with an IC50 value of 4.0 μM. Accordingly, modafinil pretreatment (10 μM) antagonized METH-induced release of the DAT substrate [3H]1-methyl-4-phenylpyridinium. Intravenous modafinil (20 and 60 mg/kg) produced dose-dependent increases in motor activity and extracellular DA, without affecting serotonin (5-HT). Analogous results were observed for GBR12909 (1 and 3 mg/kg), whereas METH (0.3 and 1 mg/kg) increased DA and 5-HT. Locomotor effects of all drugs were positively correlated with dialysate DA (P < 0.001). Interestingly, modafinil pretreatment reduced METH-induced ambulation and DA release. Our data show that modafinil interacts with DAT sites in rat brain, a property shared with agonist medications under investigation for treating cocaine dependence. Nondopaminergic mechanisms may also contribute to the pharmacology of modafinil. Finally, the results suggest that modafinil should be tested as an adjunct for treating METH addiction.Keywords
This publication has 41 references indexed in Scilit:
- Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brainPharmacology Biochemistry and Behavior, 2008
- Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addictionBiochemical Pharmacology, 2008
- Modafinil: A Review of Neurochemical Actions and Effects on CognitionNeuropsychopharmacology, 2007
- Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in ratsBehavioural Brain Research, 2007
- A Systematic Review of ModafinilThe Journal of Clinical Psychiatry, 2006
- Mining the ReceptoromeJournal of Biological Chemistry, 2005
- Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaineJournal of Neurochemistry, 2004
- In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter SubstratesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in miceEuropean Neuropsychopharmacology, 1995
- The neural substrates for the motor-activating properties of psychostimulants: A review of recent findingsPharmacology Biochemistry and Behavior, 1986